Patent Application: Reducing Fasting Blood Glucose Using Plants
Summary
The USPTO has published a new patent application detailing methods and compositions for reducing fasting blood glucose using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes oral dosage forms for health benefits including increased GLP-1 levels and reduced blood lipids.
What changed
This document is a publication of a new patent application (US20260083812A1) filed with the USPTO on September 26, 2024. The application describes methods and compositions utilizing specific plants, Dichrostachys glomerata or Cissus quadrangularis, to reduce fasting blood glucose in mammals. It also claims benefits such as increased GLP-1 levels, reduced visceral fat, and decreased blood lipids, presented in various oral dosage forms.
As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future intellectual property in the therapeutic area of glucose management and related health benefits. Companies operating in the pharmaceutical or nutraceutical sectors should be aware of this filing for competitive intelligence and potential licensing or infringement considerations.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND COMPOSITIONS FOR REDUCING FASTING BLOOD GLUCOSE IN A MAMMAL USING NATURALLY OCCURING PLANTS AND SPICES
Application US20260083812A1 Kind: A1 Mar 26, 2026
Inventors
Shil Kothari, Julius Enyoug Oben
Abstract
Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing fasting blood glucose in a mammal is provided where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.
CPC Classifications
A61K 36/87 A61P 3/08 A61K 2236/333
Filing Date
2024-09-26
Application No.
18898648
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.